Lung cancer in HIV infection

Deepthi Mani, Missak Haigentz, David M. Aboulafia

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

Lung cancer is the most prevalent nonAIDS-defining malignancy in the highly active antiretroviral therapy era. Smoking plays a significant role in the development of HIV-associated lung cancer, but the cancer risk is two to four times greater in HIV-infected persons than in the general population, even after adjusting for smoking intensity and duration. Lung cancer is typically diagnosed a decade or more earlier among HIV-infected persons (mean age, 46 years) compared to those without HIV infection. Adenocarcinoma is the most common histological subtype, and the majority of patients are diagnosed with locally advanced or metastatic carcinoma. Because pulmonary infections are common among HIV-infected individuals, clinicians may not suspect lung cancer in this younger patient population. Surgery with curative intent remains the treatment of choice for early-stage disease. Although there is increasing experience in using radiation and chemotherapy for HIV-infected patients who do not have surgical options, there is a need for prospective studies because this population is frequently excluded from participating in cancer trials. Evidence-based treatments for smoking-cessation with demonstrated efficacy in the general population must be routinely incorporated into the care of HIV-positive smokers.

Original languageEnglish (US)
Pages (from-to)6-13
Number of pages8
JournalClinical Lung Cancer
Volume13
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

HIV Infections
Lung Neoplasms
HIV
Population
Smoking
Neoplasms
Highly Active Antiretroviral Therapy
Smoking Cessation
Adenocarcinoma
Prospective Studies
Radiation
Carcinoma
Drug Therapy
Lung
Therapeutics
Infection

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Mani, Deepthi ; Haigentz, Missak ; Aboulafia, David M. / Lung cancer in HIV infection. In: Clinical Lung Cancer. 2012 ; Vol. 13, No. 1. pp. 6-13.
@article{983731d896ed4788a452a733cc0c4876,
title = "Lung cancer in HIV infection",
abstract = "Lung cancer is the most prevalent nonAIDS-defining malignancy in the highly active antiretroviral therapy era. Smoking plays a significant role in the development of HIV-associated lung cancer, but the cancer risk is two to four times greater in HIV-infected persons than in the general population, even after adjusting for smoking intensity and duration. Lung cancer is typically diagnosed a decade or more earlier among HIV-infected persons (mean age, 46 years) compared to those without HIV infection. Adenocarcinoma is the most common histological subtype, and the majority of patients are diagnosed with locally advanced or metastatic carcinoma. Because pulmonary infections are common among HIV-infected individuals, clinicians may not suspect lung cancer in this younger patient population. Surgery with curative intent remains the treatment of choice for early-stage disease. Although there is increasing experience in using radiation and chemotherapy for HIV-infected patients who do not have surgical options, there is a need for prospective studies because this population is frequently excluded from participating in cancer trials. Evidence-based treatments for smoking-cessation with demonstrated efficacy in the general population must be routinely incorporated into the care of HIV-positive smokers.",
author = "Deepthi Mani and Missak Haigentz and Aboulafia, {David M.}",
year = "2012",
month = "1",
doi = "10.1016/j.cllc.2011.05.005",
language = "English (US)",
volume = "13",
pages = "6--13",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "1",

}

Lung cancer in HIV infection. / Mani, Deepthi; Haigentz, Missak; Aboulafia, David M.

In: Clinical Lung Cancer, Vol. 13, No. 1, 01.2012, p. 6-13.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Lung cancer in HIV infection

AU - Mani, Deepthi

AU - Haigentz, Missak

AU - Aboulafia, David M.

PY - 2012/1

Y1 - 2012/1

N2 - Lung cancer is the most prevalent nonAIDS-defining malignancy in the highly active antiretroviral therapy era. Smoking plays a significant role in the development of HIV-associated lung cancer, but the cancer risk is two to four times greater in HIV-infected persons than in the general population, even after adjusting for smoking intensity and duration. Lung cancer is typically diagnosed a decade or more earlier among HIV-infected persons (mean age, 46 years) compared to those without HIV infection. Adenocarcinoma is the most common histological subtype, and the majority of patients are diagnosed with locally advanced or metastatic carcinoma. Because pulmonary infections are common among HIV-infected individuals, clinicians may not suspect lung cancer in this younger patient population. Surgery with curative intent remains the treatment of choice for early-stage disease. Although there is increasing experience in using radiation and chemotherapy for HIV-infected patients who do not have surgical options, there is a need for prospective studies because this population is frequently excluded from participating in cancer trials. Evidence-based treatments for smoking-cessation with demonstrated efficacy in the general population must be routinely incorporated into the care of HIV-positive smokers.

AB - Lung cancer is the most prevalent nonAIDS-defining malignancy in the highly active antiretroviral therapy era. Smoking plays a significant role in the development of HIV-associated lung cancer, but the cancer risk is two to four times greater in HIV-infected persons than in the general population, even after adjusting for smoking intensity and duration. Lung cancer is typically diagnosed a decade or more earlier among HIV-infected persons (mean age, 46 years) compared to those without HIV infection. Adenocarcinoma is the most common histological subtype, and the majority of patients are diagnosed with locally advanced or metastatic carcinoma. Because pulmonary infections are common among HIV-infected individuals, clinicians may not suspect lung cancer in this younger patient population. Surgery with curative intent remains the treatment of choice for early-stage disease. Although there is increasing experience in using radiation and chemotherapy for HIV-infected patients who do not have surgical options, there is a need for prospective studies because this population is frequently excluded from participating in cancer trials. Evidence-based treatments for smoking-cessation with demonstrated efficacy in the general population must be routinely incorporated into the care of HIV-positive smokers.

UR - http://www.scopus.com/inward/record.url?scp=84855714034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855714034&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2011.05.005

DO - 10.1016/j.cllc.2011.05.005

M3 - Review article

C2 - 21802373

AN - SCOPUS:84855714034

VL - 13

SP - 6

EP - 13

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 1

ER -